Age and Gender Effects on the
Pharmacokinetics of HCV NS5A Inhibitor MK-8742
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
WL Marshall1, WW Yeh1, D Stypinski2, P Auger2, L Caro1, P Jumes1, X Huang1, DP Dreyer1, H-P Feng1, T O'Reilly2, B DeGroot2, T Ward2, and JR Butterton1
1Merck & Co., Inc., Whitehouse Station NJ, USA; 2Celerion, Tempe, AZ, USA
